Thomas F. Lüscher

TL;DR: The present findings provide a novel molecular mechanism underlying increased proangiogenic effects of CD34(+) PBMCs, that is, angiomiR-126 expression/secretion.

TL;DR: Clinical evidence in support of RDN as an effective interventional technique in patients with resistant hypertension is conflicting; a number of observational studies and three randomized, controlled trials support both safety and efficacy of this new therapy but some smaller studies and the large, single-blind, randomized, sham-controlled symplicity HTN-3 trial failed to show superiority ofRDN when compared with medical therapy alone.

TL;DR: The evidence so far reported and here discussed supports the concept that pharmacological modulation of p66(Shc) expression and activity may be a novel and effective target for the treatment of atherosclerotic vascular disease as well as myocardial adaptation to hypertrophic, inflammatory and neuro-hormonal stimuli in the overloaded heart.

TL;DR: In human SMCs,ET-1 markedly potentiates proliferation to PDGF, mainly via ETA receptors, which may represent an important function of ET-1 for vascular structural changes in patients and provide new therapeutic opportunities for ET- 1 receptor antagonists.

TL;DR: In this paper, the authors investigated clinical and angiographic outcomes of sirolimus-eluting (SES) and paclitaxel-ELuting stents (PES) at 5 years as part of the SIRTAX LATE study and found no differences between SES and PES in terms of cardiac death (5.8% versus 5.7% of SES-and 21.4% of PES-treated patients), myocardial infarction (6.6% versus 6.9%; P=0.51